What is Levicept?
Levicept is a specialized biotechnology firm dedicated to the development of novel therapeutics for chronic pain, with a primary focus on osteoarthritis. The company operates at the intersection of advanced pharmacology and patient-centric care, aiming to mitigate the systemic risks associated with traditional non-steroidal anti-inflammatory drugs (NSAIDs) and the long-term dependency risks linked to opioid-based treatments. By leveraging rigorous clinical trial methodologies, Levicept seeks to establish a new standard of care that balances efficacy with long-term safety profiles, positioning itself as a critical player in the therapeutic landscape for chronic pain management.
How much funding has Levicept raised?
Levicept has raised a total of $16M across 1 funding round:
Series A
$16M
Series A (2014): $16M with participation from Gilde Healthcare, Index Ventures, and Advent Life Sciences
Key Investors in Levicept
Gilde Healthcare
Gilde Healthcare is a specialized investment firm managing over 1.4 billion euros across venture and growth strategies, focusing on businesses that enable better care at lower costs.
Index Ventures
Index Ventures is a global venture capital firm that partners with entrepreneurs from seed to IPO, known for backing transformative companies that challenge the status quo.
Advent Life Sciences
Advent Life Sciences is a venture capital and private equity firm based in the United Kingdom, specializing in the support and development of innovative life science companies.
What's next for Levicept?
Looking ahead, the strategic deployment of this financing will likely focus on the expansion of clinical trial operations and the refinement of the company's lead therapeutic candidates. As Levicept moves through its current lifecycle stage, the focus will shift toward regulatory milestones and the validation of its analgesic platform in larger patient cohorts. The backing from high-profile venture firms suggests a clear path toward commercialization or potential strategic partnerships within the pharmaceutical sector. Investors will be closely monitoring the company's ability to translate its scientific research into tangible clinical outcomes, which will be essential for securing future growth rounds and achieving long-term market penetration in the competitive pain management space.
See full Levicept company page
